Evidence map›Paper›PMID 32439936›Full record

ArticleBritish journal of cancer2020

Defining COMMD4 as an anti-cancer therapeutic target and prognostic factor in non-small cell lung cancer.

Amila Suraweera, Alex Duff, Mark N Adams, Christian Jekimovs, Pascal H G Duijf, Cheng Liu, Matthew McTaggart, Sam Beard, Kenneth J O'Byrne, Derek J Richard

Erratum issuedOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.9field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. COMMD10 inhibited DNA damage to promote the progression of gastric cancer.Journal of cancer research and clinical oncology · 2024
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Amila SuraweeraQueensland University of Technology (QUT), School of Biomedical Sciences, Institute of Health and Biomedical Innovation and Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia. amila.suraweera@qut.edu.au.ORCID http://orcid.org/0000-0002-1079-2887
Alex DuffQueensland University of Technology (QUT), School of Biomedical Sciences, Institute of Health and Biomedical Innovation and Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.
Mark N AdamsQueensland University of Technology (QUT), School of Biomedical Sciences, Institute of Health and Biomedical Innovation and Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.
Christian JekimovsQueensland University of Technology (QUT), School of Biomedical Sciences, Institute of Health and Biomedical Innovation and Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.
Pascal H G DuijfQueensland University of Technology (QUT), School of Biomedical Sciences, Institute of Health and Biomedical Innovation and Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.
Cheng LiuEnvoi Specialist Pathologists, Brisbane, QLD, Australia.
Matthew McTaggartQueensland University of Technology (QUT), School of Biomedical Sciences, Institute of Health and Biomedical Innovation and Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.
Sam BeardQueensland University of Technology (QUT), School of Biomedical Sciences, Institute of Health and Biomedical Innovation and Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.
Kenneth J O'ByrneQueensland University of Technology (QUT), School of Biomedical Sciences, Institute of Health and Biomedical Innovation and Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.
Derek J RichardQueensland University of Technology (QUT), School of Biomedical Sciences, Institute of Health and Biomedical Innovation and Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia. derek.richard@qut.edu.au.
Translational Research Institute · AUThe University of Queensland · AU

Funding

Department of Health | National Health and Medical Research Council (NHMRC) 1091589
6 · The paper itself

Abstract

backgroundNon-small cell lung cancers (NSCLC) account for 85-90% of all lung cancers. As drug resistance critically impairs chemotherapy effectiveness, there is great need to identify new therapeutic targets. The aims of this study were to investigate the prognostic and therapeutic potential of the copper-metabolism-domain-protein, COMMD4, in NSCLC.

methodsThe expression of COMMD4 in NSCLC was investigated using bioinformatic analysis, immunoblotting of immortalised human bronchial epithelial (HBEC) and NSCLC cell lines, qRT-PCR and immunohistochemistry of tissue microarrays. COMMD4 function was additionally investigated in HBEC and NSCLC cells depleted of COMMD4, using small interfering RNA sequences.

resultsBioinformatic analysis and in vitro analysis of COMMD4 transcripts showed that COMMD4 levels were upregulated in NSCLC and elevated COMMD4 was associated with poor prognosis in adenocarcinoma (ADC). Immunoblotting demonstrated that COMMD4 expression was upregulated in NSCLC cells and siRNA-depletion of COMMD4, decreased cell proliferation and reduced cell viability. Cell death was further enhanced after exposure to DNA damaging agents. COMMD4 depletion caused NSCLC cells to undergo mitotic catastrophe and apoptosis.

conclusionsOur data indicate that COMMD4 may function as a prognostic factor in ADC NSCLC. Additionally, COMMD4 is a potential therapeutic target for NSCLC, as its depletion induces cancer cell death.

Indexed as

Up-RegulationAdaptor Proteins, Signal TransducingBiomarkers, TumorCarcinoma, Non-Small-Cell LungCell Line, TumorCell ProliferationCell SurvivalComputational BiologyFemaleGene Expression Regulation, NeoplasticHumansLung NeoplasmsMaleNeoplasm StagingPrognosisSurvival AnalysisAdaptor Proteins, Signal TransducingBiomarkers, Tumor

Identifiers

PMID32439936
PMCPMC7434762
OpenAlexW4237951687

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.